Market Overview

Agios Pharmaceuticals: Q3 Earnings Insights



Shares of Agios Pharmaceuticals (NASDAQ:AGIO) were unchanged after the company reported Q3 results.

Quarterly Results

Earnings per share were up 20.99% over the past year to ($1.43), which missed the estimate of ($1.38).

Revenue of $34,706,000 higher by 33.36% year over year, which missed the estimate of $38,020,000.

Looking Ahead

Agios Pharmaceuticals hasn't issued any earnings guidance for the time being.

Agios Pharmaceuticals hasn't issued any revenue guidance for the time being.

Conference Call Details

Date: Nov 05, 2020

Time: 08:00 AM

ET Webcast URL:

Recent Stock Performance

52-week high: $56.74

52-week low: $27.77

Price action over last quarter: down 8.38%

Company Profile

Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development strategy for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval.


Related Articles (AGIO)

View Comments and Join the Discussion!

Posted-In: Earnings News